Gilead Sciences Q4 Conference Call: Live Blog

Want an edge on biotech earnings? Try this.

Gilead Sciences GILD Update:

• 04:55:05 pm: CFO Washington: Expecting 2015 product sales to be $26-27B, increase of 6-10% over 2014
• 04:54:28 pm: CFO Washington: Repaid $1B in outstanding debt in Q4
• 04:52:40 pm: CFO Washington: HCV product sales $12.4B for 2014, helped by continued launches of Sovaldi and Harvoni and geographic expansion
• 04:51:52 pm: Gilead Estimates 2015 Gross to Net Hepatitis C Drug Adjustments at 46% vs 22% at End of 2014
• 04:48:52 pm: HIV: In 2014, Gilead continues clinical and commercial success, $1.9B in sales in the Q4 and $6.3B in sales for the whole year, lead by Complera and Stribild
• 04:48:08 pm: 80% of new HIV patients started treatment on a Gilead product, 70% of which were on Truvada
• 04:46:15 pm: We expect 2015 gross to net adjustments in product in the US to be 46%, over double in 2014 which was 22%
• 04:42:38 pm: 140,000 have started HCV therapy on a Gilead product in the United States.
• 04:41:08 pm: CEO Martin: Board has approved quarterly cash dividend program and $15B, 5-year repurchase. 2015 will be as busy as 2014, and will continue to provide collaboration and medication to those in need. I am proud of our progress thus far.
• 04:36:46 pm: CEO John Martin: Sovaldi has been approved in India and currently has 15,000 under treatment
• 04:30:00 pm: Conference call begins
• 04:26:34 pm: Gilead conference call expected to start at 4:30 pm ET. Click here to listen to the webcast.
• 04:07:50 pm: Gilead Sciences Announces Initial Dividend Of $0.43/share
• 04:07:06 pm: Gilead Sciences Announces $15B Buyback Program
• 04:04:04 pm: Gilead Reports Q4 Adj. EPS $2.43 vs $2.21 Est., Sales $7.31B vs $6.74B Est.
02:13:45 pm: Gilead Sciences earnings preview.